As the battle over biosimilar drugs intensifies, Johnson & Johnson (JNJ) plans to host a meeting to solicit advice from experts about maintaining the dominance of its Remicade rheumatoid arthritis treatment. Such efforts are hardly unusual, but the nature of its overture is troubling some experts, who complain the health care giant is pursuing a tactic that will only maintain high prices.

Next month, the company hopes to hold what is called an advisory board meeting in Nashville, Tenn., where a group of medical experts will be asked to “identify opportunities to differentiate Remicade” from one or more biosimilar medicines. A biosimilar, you may recall, is a nearly identical variant of a brand-name biologic medicine and is expected to provide the same result in patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy